• Touret et al. (2019). Phylogenetically based establishment of a dengue virus panel as a tool in dengue drug discovery. Antiviral Res. 168: 109–113. doi: 10.1016/j.antiviral.2019.05.005
• Touret et al. (2020). In vitro screening of an FDA-approved chemical library reveals potential inhibitors of SARS-CoV-2. Sci Rep. 10: 13093. doi: 10.1038/s41598-020-70143-6
• Kaptein et al. (2021). A pan-serotype dengue virus inhibitor targeting the NS3–NS4B interaction. Nature. doi: 10.1038/s41586-021-03990-6
• Touret et al. (2021). Preclinical evaluation of Imatinib does not support its use against SARS-CoV-2. Antiviral Res. 193: 105137. doi: 10.1016/j.antiviral.2021.105137
• Hernández et al. (2022). Inhibitors of arenavirus and SARS-CoV-2 exoribonucleases identified by fluorescence polarization. Antiviral Res. 204: 105364. doi: 10.1016/j.antiviral.2022.105364
• Goethals et al. (2023). Blocking NS3–NS4B interaction inhibits dengue virus in non-human primates. Nature. 615: 678–686. doi: 10.1038/s41586-023-05790-6
• Bouzidi et al. (2024). Generation and evaluation of protease inhibitor-resistant SARS-CoV-2 strains. Antiviral Res. 222: 105814. doi: 10.1016/j.antiviral.2024.105814
• Bouzidi et al. (2024). Genomic surveillance reveals a dengue 2 epidemic lineage with reduced Mosnodenvir sensitivity. Nat Commun. 15: 8667. doi: 10.1038/s41467-024-52819-z
• Chaput et al. (2025). Human liver spheroids as a model for antiviral evaluation against BSL-3 haemorrhagic fever viruses. Antiviral Res. 239: 106188. doi: 10.1016/j.antiviral.2025.106188